SecBot SecBot
SECBOTREPLAY Home › Report › BDX

BDX · BD filed recast historical financial information reflecting the…

BECTON DICKINSON & CO · 8-K filed Apr 2, 2026 at 16:18 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Apr 2, 2026 at 16:18 ET

BD filed recast historical financial information reflecting the spin-off of its Biosciences and Diagnostic Solutions business (completed Feb 9, 2026) as discontinued operations. The recast New BD continuing operations show Q1 fiscal 2026 revenue of $4.486B, up 3.5% reported and 2.5% on a currency-neutral basis versus the prior-year recast period, with adjusted diluted EPS from continuing operations of $2.50, down from $2.78 in the year-ago period.

  • BD completed the spin-off of its Biosciences and Diagnostic Solutions business and combination with Waters Corporation on February 9, 2026.
  • Recast New BD continuing operations Q1 fiscal 2026 revenue: $4.486B, up 3.5% reported and 2.5% FXN vs. $4.333B in the prior-year recast period.
  • Recast New BD continuing operations adjusted diluted EPS (non-GAAP) for Q1 fiscal 2026: $2.50, down from $2.78 in the prior-year recast period.
  • GAAP diluted EPS from continuing operations for recast New BD: $1.09 vs. $0.50 in the prior-year recast period.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access